'Rare' uptick in pharma's corporate reputation

The corporate reputation of pharma according to rare disease patient groups has risen to levels not seen for five years with Roche taking the top spot for Big Pharma companies followed by Boehringer Ingelheim in second place and AstraZeneca and Sanofi tying for bronze.